This study investigated factors associated with discontinuation in double-blind, randomized, placebo-controlled trials (DBRPCTs) of second-generation antipsychotics (SGAs) for acute schizophrenia, with a view to establishing what factors were associated with all-cause discontinuation. 77 eligible studies (96 comparisons; n = 22,678) were included in this study. Thirty-one factors potentially affecting all-cause discontinuation, related to the participants, study design, and drugs, were included in a meta-regression analysis that examined the factors associated with discontinuation rates in treatment and placebo groups and/or the treatment–placebo group difference in discontinuation. Smaller improvements in Positive and Negative Syndrome Scale total scores from baseline to endpoint were associated with higher discontinuation rates in both the treatment and placebo groups, and smaller response rates in the treatment group were associated with higher discontinuation rates in the treatment group. These factors were also associated with the treatment–placebo group difference in discontinuation. Although the risk of weight gain from SGA use was not associated with discontinuation rates in either the treatment or placebo groups, SGAs with a risk of weight gain were associated with a larger treatment–placebo group difference in discontinuation, although the reason is unknown. Factors associated with discontinuation rates in both treatment and placebo groups did not influence the treatment–placebo group difference in discontinuation. The efficacy and the risk of weight gain of SGAs seemed to influence treatment–placebo group difference in discontinuation in DBRPCTs of SGAs for acute schizophrenia.

这项研究调查了第二代抗精神病药物（SGA）在急性精神分裂症的双盲，随机，安慰剂对照试验（DBRPCT）中与停药有关的因素，以期确定哪些因素与全因停药有关。这项研究包括77项合格研究（96个比较； n = 22,678）。一项荟萃回归分析包括与参与者，研究设计和药物有关的可能影响全因停药的31个因素，该回归分析检查了与治疗组和安慰剂组和/或治疗-安慰剂停药率相关的因素。停药组差异。从基线到终点，阳性和阴性综合征量表总分的较小改善与治疗组和安慰剂组的较高停药率相关，治疗组较小的缓解率与治疗组较高的停药率相关。这些因素也与停药的治疗-安慰剂组差异有关。尽管无论是在治疗组还是在安慰剂组中，使用SGA引起体重增加的风险均与停用率无关，但尽管原因不明，但具有体重增加风险的SGA与治疗-安慰剂组的停药率差异较大有关。在治疗组和安慰剂组中与停药率相关的因素均不影响治疗–安慰剂组在停药方面的差异。